Inhalant Use Disorder
Inhalant use disorder is a psychiatric condition that applies to the deliberate use of inhalants, not to the accidental inhalation of toxic or psychoactive substances, even if they are the same substances that are people inhale when they have inhalant use disorder, and even if they produce identical effects.
Cluster Number:
Wiki Number: W105
Diagnosis: Inhalant Use Disorder
US Patients: 38 of 50 states make sales of inhalants illegal below age 18
World Patients:
Sex Ratio:
Age Onset: 10-12 years, can be fatal
Brain Area: Individual uses can lower oxygen levels & affect heart rhythms; regular use, harm to brain, heart, kidneys and liver
Symptoms: chemicals whose vapors can be breathed in for intoxication; “sniffing, huffing or bagging”; solvents, gases, medical drugs
Progression: By type: petroleum products, gases, medical anesthetics; abuses vary by product; pregnant users may injure fetuses.
Causes: Hostility to accepted cultural norms
Medications: None listed.
Therapies: None listed.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Prediction of readmission in patients with acute exacerbation of chronic obstructive pulmonary disease within one year after treatment and dischargeby Lili Chen on October 16, 2021
CONCLUSIONS: The XGBoost model showed a better predictive value in predicting the risk of readmission within one year in the AECOPD patients than the logistic regression model. The findings of our study might help identify patients with a high risk of readmission within one year and provide timely treatment to prevent the reoccurrence of AECOPD.
- The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practiceby Ian M Adcock on October 16, 2021
The use of inhaled corticosteroids (ICS) in combination with inhaled bronchodilators for patients with chronic obstructive pulmonary disease (COPD) is a common practice in primary care settings. However, ICS-containing therapies may be less effective in patients with COPD compared with asthma, and in individuals with COPD who continue to smoke cigarettes. Preclinical studies suggest that inflammation in COPD is very different than in asthma. Glucocorticoid receptor (GR) functioning and other...
- Lead (Pb) and neurodevelopment: A review on exposure and biomarkers of effect (BDNF, HDL) and susceptibilityby Claudia Gundacker on October 16, 2021
Lead (Pb) is a ubiquitous environmental pollutant and a potent toxic compound. Humans are exposed to Pb through inhalation, ingestion, and skin contact via food, water, tobacco smoke, air, dust, and soil. Pb accumulates in bones, brain, liver and kidney. Fetal exposure occurs via transplacental transmission. The most critical health effects are developmental neurotoxicity in infants and cardiovascular effects and nephrotoxicity in adults. Pb exposure has been steadily decreasing over the past...
- Evaluation of anti-inflammatory and immunomodulatory activity of Chyawanprash on particulate matter-induced pulmonary disease in miceby Satyendra Kumar on October 15, 2021
CONCLUSION: These findings suggest that CP has potential benefit in protecting from harmful effects caused by air pollutants such as PM(2.5).